start portlet menu bar end portlet menu bar

Comparative study of the safety of 3 trivalent inactivated vaccines against Swine Erysipelas, Porcine Parvovirus and Leptospira in gilts

Home Kennis Comparative study of the safety of 3 trivalent inactivated vaccines against Swine Erysipelas, Porcine Parvovirus and Leptospira in gilts

Comparative study of the safety of 3 trivalent inactivated vaccines against Swine Erysipelas, Porcine Parvovirus and Leptospira in gilts

The aim of this study was to compare the safety of 3 different commercial trivalent vaccines against these reproductive diseases in sows.

Download dit artikel

348 kB

Over dit artikel

Gepubliceerd in

APVS Congress, 2017

Datum

12 mei 2017

Auteurs

Boix, O.; Camprodon, A.; Sánchez-Matamoros, A.

Samenvatting

Results clearly show the optimum performance obtained with ERYSENG® PARVO/LEPTO vaccine, which achieved better safety levels than its competitors. These differences may trigger lower feed intake by the sow, affect the sow’s milk production and consequently result in a lower weight gain by the piglets.

Gerelateerde diensten

HIPRA Diagnos

Gerelateerde producten

ERYSENG® PARVO/LEPTO

Gerelateerde publicaties

Comparative study of the humoral response and safety effects of two commercial reproductive vaccines under field conditions in breeding sows Neutralizing antibodies against PRRS virus in breeding pigs vaccinated with the combined administration of UNISTRAIN® PRRS and ERYSENG® PARVO Impact of sow vaccination during lactation on piglet performance

Delen

De inhoud van deze website is speciaal bedoeld voor dierenartsen. Wanneer u klikt op "Accepteren" bevestigt u dat u een dierenarts bent. Klik anders op "Weigeren" en neem contact op met een dierenarts.

start portlet menu bar end portlet menu bar

Zie ook

Publicaties

Efficacy of a new inactivated vaccine against Chlamydia abortus and Salmonella enterica se...

23-09-2019
Omschrijving ziekte

Mycoplasma in Swine: Keys to an accurate Diagnosis

31-01-2020
Nieuws

Why professionals choose Hipradermic®, our intradermal vaccination device?

22-04-2020